Helle-Brit Fiebrich-Westra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helle-Brit Fiebrich-Westra has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
C. J. P. Op ’T Hoog
Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands
1 shared publicationE. Boerrigter
Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands
1 shared publicationE. J. Smolders
Division of Data Science, Isala Hospital, Zwolle, The Netherlands
1 shared publication- Eline G. M. Steenhuis
Department of Pulmonology, Isala, Zwolle, The Netherlands
1 shared publication H.L. van Westreenen
Dept of Surgery, Isala, Dokter van Heesweg 2, 8025, AB Zwolle, the Netherlands
1 shared publication- Irene Elisabeth Gerarda van Hellemond
Department of Medical Oncology, Catharina Hospital, Eindhoven, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Introducing Whole Genome Sequencing to Adolescents and Young Adults (AYA) with Poor-prognosis Cancer into Standard Oncology Care: What do they know, expect and value?
Purpose: Adolescents and young adults (AYAs; aged 18–39 years at cancer diagnosis) with poor-prognosis cancer may benefit from whole-genome sequencing (WGS) to optimise treatment selection and refine diagnosis. Given their distinct life phase, AYAs may have specific expectations, motivations, and information needs regarding WGS. This study explores AYAs' knowledge, expectations, motivations, and communication preferences prior to disclosure of WGS results.Methods: This study presents a cross-sectional analysis of baseline data from the longitudinal multicentre mixed-methods GEN-impact-AYA study, collected prior to disclosure of WGS results. Participants (N = 105) completed items assessing knowledge and expectations of WGS; factors influencing the decision to pursue WGS; attitudes toward WGS; perceived advantages and disadvantages; and satisfaction with WGS and the information provided.Results: Overall, AYAs were satisfied with their decision to have WGS. Main motivations included its potential to support treatment decisions (77.7%) and a desire to help future patients (53.4%). The majority (59.0%) had good knowledge of WGS. AYAs estimated, on average, a 60.5% probability that WGS would contribute to their diagnosis or treatment, on a scale from 0 (very unlikely) to 100% (very likely). However, many AYAs reported receiving limited information on the likelihood of treatment implications and potential germline findings.Conclusion: AYAs with poor-prognosis cancer receiving paired tumour–normal WGS recognise its potential to guide treatment decisions and contribute to future care. However, their expectations often reflect hope and may exceed the realistic clinical yield of WGS. Clinicians should clearly communicate tumour-specific implications of WGS, including potential germline findings. Given the high information-seeking behaviour among AYAs, directing them to trustworthy (online) resources before disclosure of WGS results is essential.
- 27 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntroducing Whole Genome Sequencing to Adolescents and Young Adults (AYA) with Poor-prognosis Cancer into Standard Oncology Care: What do they know, expect and value?
Purpose: Adolescents and young adults (AYAs; aged 18–39 years at cancer diagnosis) with poor-prognosis cancer may benefit from whole-genome sequencing (WGS) to optimise treatment selection and refine diagnosis. Given their distinct life phase, AYAs may have specific expectations, motivations, and information needs regarding WGS. This study explores AYAs' knowledge, expectations, motivations, and communication preferences prior to disclosure of WGS results.Methods: This study presents a cross-sectional analysis of baseline data from the longitudinal multicentre mixed-methods GEN-impact-AYA study, collected prior to disclosure of WGS results. Participants (N = 105) completed items assessing knowledge and expectations of WGS; factors influencing the decision to pursue WGS; attitudes toward WGS; perceived advantages and disadvantages; and satisfaction with WGS and the information provided.Results: Overall, AYAs were satisfied with their decision to have WGS. Main motivations included its potential to support treatment decisions (77.7%) and a desire to help future patients (53.4%). The majority (59.0%) had good knowledge of WGS. AYAs estimated, on average, a 60.5% probability that WGS would contribute to their diagnosis or treatment, on a scale from 0 (very unlikely) to 100% (very likely). However, many AYAs reported receiving limited information on the likelihood of treatment implications and potential germline findings.Conclusion: AYAs with poor-prognosis cancer receiving paired tumour–normal WGS recognise its potential to guide treatment decisions and contribute to future care. However, their expectations often reflect hope and may exceed the realistic clinical yield of WGS. Clinicians should clearly communicate tumour-specific implications of WGS, including potential germline findings. Given the high information-seeking behaviour among AYAs, directing them to trustworthy (online) resources before disclosure of WGS results is essential.
- Open Access
- 30 July 2026
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 42 (2) , 509-518
Optimizing paclitaxel pretreatment: cetirizine as a safe and patient-centered alternative to clemastine
- 30 July 2026
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 42 (2) , 509-518
Open AccessOptimizing paclitaxel pretreatment: cetirizine as a safe and patient-centered alternative to clemastine
- 1 November 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (11) , 2068-2073
Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: A pilot study
- 1 November 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (11) , 2068-2073
Feasibility of volatile organic compound in breath analysis in the follow-up of colorectal cancer: A pilot study